Showing results (1-10 of 86) with videos related to

Sort By:
Pageof 9
Expert Opinion on Drug Safety|August 14, 2012
Clinical safety of biosimilar recombinant human erythropoietinsIvo Abraham, Karen MacDonald
Leukemia Research|May 6, 2021
Conversion to supportive care with biosimilar pegfilgrastim-cbqv enables budget-neutral expanded access to R-CHOP treatment in non-Hodgkin lymphomaAli McBride, Karen MacDonald, Ivo Abraham
Expert Opinion on Drug Safety|February 20, 2013
Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factorsIvo Abraham, Soba Tharmarajah, Karen MacDonald
Journal of Medical Economics|July 17, 2024
Cost-efficiency and budget-neutral expanded access modeling of pembrolizumab versus the novel PD-1 inhibitor toripalimab in locally advanced or metastatic nonsquamous non-small cell lung cancerKaren MacDonald, Marc Pondel, Ivo Abraham
Journal of Medical Economics|March 15, 2024
Cost-efficiency and budget-neutral expanded access modeling of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinomaKaren MacDonald, Marc Pondel, Ivo Abraham
Future Oncology (London, England)|August 12, 2021
Conversion to biosimilar pegfilgrastim-cbqv enables budget-neutral access to FOLFIRINOX treatment for metastatic pancreatic cancerKaren MacDonald, Neda Alrawashdh, Ali McBride, et al.
Journal of Medical Economics|October 7, 2020
Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegfilgrastim-cbqvKaren MacDonald, Ali McBride, Neda Alrawashdh, et al.
Future Oncology (London, England)|November 8, 2021
Expanded access to anticancer treatments from conversion to biosimilar pegfilgrastim-cbqv in US breast cancer patientsAli McBride, Neda Alrawashdh, Karen MacDonald, et al.
Journal of Medical Economics|May 18, 2021
Cost-efficiency and expanded access modeling of conversion to biosimilar trastuzumab-dkst with or without pertuzumab in metastatic breast cancerAli McBride, Karen MacDonald, Adolfo Fuentes-Alburo, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 30, 2017
"Real-life" Effectiveness Studies of Omalizumab in Adult Patients with Severe Allergic Asthma: Meta-analysisAbdulaziz Alhossan, Christopher S Lee, Karen MacDonald, et al.
Pageof 9